Immunome is developing first-in-class cancer therapies by unlocking the tumor-educated B cell response from patients. Their proprietary discovery engine identifies antibody-target pairs by interrogating the patient response with unparalleled depth, breadth, and speed. Using this rich source of antibody-target pairs, Immunome is developing new cancer therapies and exploring vast, untapped areas of cancer biology.